DELHI HIGH COURT REJECTS GERMAN DRUGMAKER BAYER’S PLEA ON CIPLA’S NEXAVAR COPYCAT

Search News

THE Delhi High Court (HC) has dismissed an appeal by German drugmaker Bayer that sought to stop Cipla from obtaining a marketing approval from the country’s drug regulator to launch a low-cost version of patented cancer drug Nexavar in India.

   This ruling could pre-empt similar attempts by global pharma companies from getting a legal mandate to introduce patent linkage system in India. Under such a system, the local drug regulator cannot give marketing approval to copycat versions of drugs patented in India.

   Amar Lulla, joint managing director of Cipla, said the company expects to launch the generic version of Nexavar within two months at less than half the price of Bayer’s version. The medicine, used to treat renal cancer, cost Rs 2.85 lakh for a monthly dose of 120 tablets. However, if Cipla launches the drug, Bayer can move the court against the Mumbai-based company. If found guilty of patent infringement, Cipla may have to pay damages to the German patent holder.

   The Delhi HC upheld an earlier ruling by the same court, which dismissed an appeal seeking to stop Indian generic companies to launch low-priced versions of patented drugs in India.

   “The court does not find any ground having been made out to reverse the well reasoned judgment of learned single Judge in which we fully concur. The appeal is accordingly dismissed,” a division bench of the Delhi HC comprising chief justice AP Shah and Justice Muralidhar said. It also rejected Bayer’s contention that Cipla’s generic drug was spurious.

   The bench also ruled that drugs regulator Drug Controller General of India’s (DCGI) powers and jurisdiction are circumscribed by the Drugs and Cosmetics Act 1940, and not by the Patents Act. “This is a historic judgement laying down the rules for access to generic drugs and impacts the entire drug industry. The ruling will also support India’s stand at the World Trade Organisation against the ongoing seizures of drugs at ports in Europe,” said Pratibha M Singh, who represented Cipla in the case.

Find Lawyer / Law Firm

Importance of Immigration Lawyers

As Indians we know India in itself is an amazing nation and even the world agrees with that, however, grass is always greener on the other side and that is why Indians desire to immigrate a More

Legal Consultation - Consult over phone, chat or send questions

Helplinelaw can set up your session with quality and experienced lawyers to discuss and resolve your legal matters. You can avail consultation in form of sending questions, phone call or webchat discussion  More